The latest news from academia, regulators
research labs and other things of interest
Posted: January 2, 2008
First Annual Conference on Nanotechnology Law, Regulation and Policy
(Nanowerk News) The Food and Drug Law Institute is sponsoring an annual conference on Nanotechnology Law Regulation and Policy, February 28-29, 2008, at the L'Enfant Plaza Hotel, in Washington, D.C. It will enable food and drug industry representatives to find out what‚s happening international and domestically on nanotech regulation, how venture capitalists look at the future of nanotechnology, and what the leading corporations, scientific laboratories and academic centers on focusing on in the dynamic field.
Nanotechnology was incorporated into more than $50 billion in manufactured goods last year, according to Lux Research. By 2014, the market will grow to $2.6 trillion. By 2011, over $15 billion in nano-enabled drugs and therapeutics will be sold—up from more than $3 billion in 2006. And industry experts project that nanotechnology will be incorporated into $20 billion worth of consumer food products by 2010.
Yet, despite this rapid commercialization, no nano-specific regulation exists anywhere in the world. Most regulatory agencies remain in an information-gathering mode—lacking the legal and scientific tools, information and resources they need to adequately oversee exponential nanotechnology market growth.
Now, for the first time, you’ll get to meet all the top officials from these government departments in one place and learn of their plans for regulating food and drug nanotech products. You’ll hear what’s really happening in Europe and Asia, on Wall Street, in the corridors of major corporations, in the more advanced laboratories, at forward-thinking universities and in the halls of Congress.
And you’ll also get the answers to those questions you’ve been talking to your colleagues about for the last several months:
* How is FDA going to implement its Nanotechnology Task Force Report?
* How is OSHA going to deal with nanotech issues in the workplace?
* Is Congress ready to act on nanotechnology if federal regulators don’t?
* What first and second generation nanotechnology products are already on the market, and what’s to come?
* Do Europe and Asia approach nanotechnology safety and oversight differently
than the United States?
* When it comes to nanotechnology, should size make a regulatory difference?
Who Should Attend
Pharmaceutical firm representatives, nanotech development specialists, venture capitalists, in-house and outside legal counsel, nanotech policy officials.